Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield ...

Weight loss drugs like Wegovy and Zepbound are getting cheaper, if you are willing to pay out of pocket for the medications.

Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE ...

About Veru Inc. Veru is a late clinical stage biopharmaceutical ... patients receiving semaglutide (Wegovy®). The trial met its prespecified primary endpoint with a statistically significant ...

Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...

Veru is a late clinical-stage biopharmaceutical ... greater than or equal to 60 years of age receiving semaglutide, which is Wegovy, for weight for chronic weight management.

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

The GLP-1 RA may be either WEGOVY (semaglutide) and/or Zepbound® (tirzepatide ... is on Track to be Available for Phase 3 Clinical Studies and Commercialization Veru is currently developing a novel, ...

The GLP-1 RA may be either WEGOVY (semaglutide ... to be Available for Phase 3 Clinical Studies and Commercialization Veru is currently developing a novel, patentable, modified release oral ...

Veru Inc. updates on its Phase 2b clinical trials ... patients receiving semaglutide (Wegovy Enobosarm + semaglutide treatment resulted in dose dependent greater loss of fat mass compared to ...

-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI ...